Syndax Pharma发布了Revumenib治疗血液中R/R mNPM 1急性骨髓性白血病患者的AUGMENT-101试验的关键2期部分数据

– Primary endpoint met in R/R mNPM1 AML patients in pivotal Phase 2 portion of the AUGMENT-101 trial –

– Robust remission rates in heavily pre-treated R/R mNPM1 AML population with nearly 50% overall response rate –

– sNDA for revumenib in R/R mNPM1 AML submitted in April 2025 –

NEW YORK, May 07, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that data from the pivotal Phase 2 portion of the AUGMENT-101 trial of revumenib, a first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) have been published in Blood.